Zydus Cadila gets USFDA gesture to showcase its disease treatment infusion Kumar Jeetendra | September 11, 2020 New Delhi, Sep 11 (PTI) Medication firm Zydus Cadila on Friday said it has received final nod in the US health regulator to advertise its generic Doxorubicin Hydrochloride Liposome injection, used for treatment of certain types of cancer, in the American market. The company has received final approval from the United States Food and Drug …
Granules India arm gets USFDA gesture for ADHD treatment drug Kumar Jeetendra | September 11, 2020 New Delhi, Sep 11 (PTI) Medication firm Granules India Friday said its subsidiary has received marketing approval from the US health regulator for Dexmethylphenidate HCl extended-release capsules, used for the treatment of attention-deficit hyperactivity disorder (ADHD). The approved product is bioequivalent to the reference listed drug Focalin XR of Novartis AG. In a BSE filing, …
RedHill Biopharma’s Opaganib Demonstrates Complete Inhibition of SARS-CoV-2 Kumar Jeetendra | September 8, 2020 TEL AVIV, Israel and RALEIGH, N.C., Sept. 08, 2020 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that opaganib1 demonstrated potent inhibition of SARS-CoV-2, the virus that causes COVID-19, achieving complete blockage of viral replication in an in vitro model of human lung bronchial tissue. …
Protein-based COVID-19 vaccine trial launched by Sanofi and GSK Kumar Jeetendra | September 3, 2020 French drugmaker Sanofi and its British peer GSK have begun a clinical trial for a protein-based COVID-19 vaccine candidate, as pharmaceutical firms race to develop treatments against the coronavirus pandemic. Sanofi and GSK said in a joint statement on Thursday they’d begun the”Stage 1/2″ trial for their adjuvanted COVID-19 vaccine, and that they expect to …
Lupin dispatches generic rheumatoid arthritis drug in US market Kumar Jeetendra | September 2, 2020 Medicine manufacturer Lupin on Wednesday said it has established Leflunomide pills, used to treat rheumatoid arthritis, even in the US marketplace. The business has established the product in 10 mg and 20 mg strengths after receiving the approval by the US Food and Drug Administration (USFDA) before, Lupin said in a statement. The item could …
Zydus Cadila gets USFDA gesture for muscle relaxant infusion Kumar Jeetendra | September 2, 2020 Zydus Cadila has obtained final acceptance by the US Food and Drug Administration (USFDA) to advertise Cisatracurium Besylate Injection USP at the potency of 20 milligrams (base)/10 mL (two mg/mL) multiple-dose vial, Cadila Healthcare stated in a regulatory filing on Wednesday. The drug will be produced in Liva plant of Cadila Healthcare Ltd.. Zydus Cadila …
Biocartis Expands Collaboration with LifeArc Kumar Jeetendra | September 1, 2020 Mechelen, Belgium, and London, UK, 1 September 2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the expansion of its collaboration with LifeArc, a UK based independent medical research charity, with a new agreement aimed at the development of highly innovative prototype assays in the …
Sanofi more certain about its coronavirus immunizations Kumar Jeetendra | August 29, 2020 Sanofi’s assurance in its own coronavirus vaccine candidates has increased this summer as the French drugmaker prepares to commence clinical trials, its chief executive told Reuters. The company is working on two of their more than 150 potential vaccines being developed throughout the world to tackle the COVID-19 pandemic, which has maintained over 831,000 lives …
Alembic Pharma gets USFDA’s’ speculative endorsement for type 2 diabetes DRUG Kumar Jeetendra | August 29, 2020 In a regulatory filing, Alembic Pharmaceuticals said it has received tentative approval by the US Food and Drug Administration (USFDA) for both Empagliflozin and Linagliptin pills in the strengths of 10 mg/5 mg and 25 mg/5 mg. Alembic Pharma stated it is now in litigation with Boehringer at District Court of Delaware and launch of …
FDC dispatches 2 variations of Favipiravir in India at Rs 55 for each tablet Kumar Jeetendra | August 25, 2020 Drug firm FDC Ltd on Tuesday said it has established two variants of this COVID-19 drug Favipiravir under the brand names PiFLU and Favenza. The Drug Controller General of India (DCGI) had previously approved the use of Favipiravir, an off patent, oral antiviral drug that’s been demonstrated to quicken clinical healing from COVID-19 patients with …
AstraZeneca begins preliminary of antibody treatment for COVID-19 Kumar Jeetendra | August 25, 2020 AstraZeneca said on Tuesday it began early stage trials to get an antibody-based treatment for the prevention and treatment of COVID-19, as the British drugmaker also ploughs on with its vaccine candidate. The trial will assess if AZD7442, a blend of two monoclonal antibodies, is tolerable and safe in up to 48 healthy participants between …
Moderna finishes up cutting edge chats with EU for COVID-19 immunization gracefully Kumar Jeetendra | August 24, 2020 Moderna Inc said on Monday it’s concluded advanced exploratory talks with the European Commission to supply 80 million doses of its COVID-19 vaccine candidate. The potential arrangement provides for an option for member states to get an additional 80 million doses for a total of around 160 million doses, the business said.
